DaeWoong Pharmaceutical: Safety of Bersiporocin Reaffirmed
DaeWoong Pharmaceutical announced that its idiopathic pulmonary fibrosis (IPF) drug candidate Bersiporocin received a recommendation to continue its global Phase 2 clinical trial.
The third Independent Data Monitoring Committee (IDMC) review, held on September 23, confirmed the safety and continuation of the study, with 94 patients enrolled out of 102 planned across Korea and the U.S.
The IDMC conducted an in-depth evaluation of interim safety data from 89 enrolled patients and found no significant safety concerns that would impact the trial's continuation.
- 94 participants enrolled, representing approximately 92% of the target population (102 patients)
- The study is progressing as planned
Author's summary: DaeWoong Pharmaceutical's Bersiporocin trial continues after safety reaffirmed.
More News
- Why Experienced Lawyers Matter in a Personal Injury Case | NorthPennNow
- Key Asks from Government – As Staffordshire Finalises LGR Submission - Staffordshire County Council Newsroom
- BioDlink Biopharm Co., Ltd.: BioDlink Completes First International Shipment of Bevacizumab to Colombia
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- ICYMI: AAO 2025 showcases new technologies and continued research | Ophthalmology Times - Clinical Insights for Eye Specialists
- West Indies ease past Bangladesh in first T20I
- Philippines economy to grow 5.6% in 2025 – Fitch
- The environmental impact of the 2026 World Cup
- Landmark New Report Shows Canadian Lobbyists Represent Major Polluters Alongside Environmental Groups
- “Seeded” exhibit showcases impact of investment